Bortezomib-based combinations in the treatment of non-small-cell lung cancer.

Angela M. Davies, Primo N Lara, Philip Mack, Paul H. Gumerlock, Richard J Bold, David R Gandara

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Lung cancer is the most common cause of cancer-related death among men and women in the United States. Current trials are focusing on the integration of novel therapeutic agents into current non-small-cell lung cancer (NSCLC) treatment paradigms. Bortezomib, a small-molecule proteasome inhibitor, has single-agent activity in NSCLC and in combination with agents commonly used in NSCLC. This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date.

Original languageEnglish (US)
JournalClinical lung cancer.
Volume7 Suppl 2
StatePublished - Oct 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Proteasome Inhibitors
Therapeutics
Lung Neoplasms
Clinical Trials
Bortezomib
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Bortezomib-based combinations in the treatment of non-small-cell lung cancer. / Davies, Angela M.; Lara, Primo N; Mack, Philip; Gumerlock, Paul H.; Bold, Richard J; Gandara, David R.

In: Clinical lung cancer., Vol. 7 Suppl 2, 10.2005.

Research output: Contribution to journalArticle

@article{39ecb4b5b31447e5a600a0d262bbf498,
title = "Bortezomib-based combinations in the treatment of non-small-cell lung cancer.",
abstract = "Lung cancer is the most common cause of cancer-related death among men and women in the United States. Current trials are focusing on the integration of novel therapeutic agents into current non-small-cell lung cancer (NSCLC) treatment paradigms. Bortezomib, a small-molecule proteasome inhibitor, has single-agent activity in NSCLC and in combination with agents commonly used in NSCLC. This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date.",
author = "Davies, {Angela M.} and Lara, {Primo N} and Philip Mack and Gumerlock, {Paul H.} and Bold, {Richard J} and Gandara, {David R}",
year = "2005",
month = "10",
language = "English (US)",
volume = "7 Suppl 2",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",

}

TY - JOUR

T1 - Bortezomib-based combinations in the treatment of non-small-cell lung cancer.

AU - Davies, Angela M.

AU - Lara, Primo N

AU - Mack, Philip

AU - Gumerlock, Paul H.

AU - Bold, Richard J

AU - Gandara, David R

PY - 2005/10

Y1 - 2005/10

N2 - Lung cancer is the most common cause of cancer-related death among men and women in the United States. Current trials are focusing on the integration of novel therapeutic agents into current non-small-cell lung cancer (NSCLC) treatment paradigms. Bortezomib, a small-molecule proteasome inhibitor, has single-agent activity in NSCLC and in combination with agents commonly used in NSCLC. This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date.

AB - Lung cancer is the most common cause of cancer-related death among men and women in the United States. Current trials are focusing on the integration of novel therapeutic agents into current non-small-cell lung cancer (NSCLC) treatment paradigms. Bortezomib, a small-molecule proteasome inhibitor, has single-agent activity in NSCLC and in combination with agents commonly used in NSCLC. This article will review the rationale and preclinical data supporting bortezomib combinations and the clinical trials with bortezomib alone and in combination in NSCLC to date.

UR - http://www.scopus.com/inward/record.url?scp=33644691911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644691911&partnerID=8YFLogxK

M3 - Article

C2 - 16250929

AN - SCOPUS:33644691911

VL - 7 Suppl 2

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

ER -